论文部分内容阅读
目的观察反流性食管炎应用奥美拉唑联合伊托必利治疗的临床疗效。方法选择2015年1月-2016年6月滨海新区汉沽中医医院消化科住院收治110例反流性食管炎患者为研究对象,以随机数字表法分组,分为对照组和观察组,每组各55例。对照组服用促胃动力药物伊托必利与抑胃酸药物法莫替丁治疗,观察组给予伊托必利联合质子泵抑制剂奥美拉唑治疗,观察两组服药后的治疗效果并进行生存质量评分。结果观察组治疗总有效率为94.55%,明显高于对照组的78.18%,差异有统计学意义(P<0.05),观察组治疗后生存质量评分明显高于对照组,差异有统计学意义(P<0.05)。结论对反流性食管炎采用奥美拉唑联合伊托必利治疗能够有效缓解患者的临床症状,提高治疗效果,降低不良反应发生率,值得临床推广应用。
Objective To observe the clinical effect of omeprazole combined with itopride on reflux esophagitis. Methods From January 2015 to June 2016, 110 patients with reflux esophagitis admitted to the Hangu Hospital of Traditional Chinese Medicine, Binhai New District, were randomly divided into control group and observation group 55 cases. The control group was treated with itost-promoting drug, itopride and the gastric acid-fasting drug famotidine. The observation group was treated with itopride and proton pump inhibitor omeprazole. The therapeutic effect and survival of the two groups were observed Quality Score. Results The total effective rate of the observation group was 94.55%, which was significantly higher than that of the control group (78.18%), the difference was statistically significant (P <0.05). The quality of life score of the observation group was significantly higher than that of the control group P <0.05). Conclusion The combination of omeprazole and itopride in the treatment of reflux esophagitis can effectively alleviate the clinical symptoms, improve the therapeutic effect and reduce the incidence of adverse reactions, which is worthy of clinical application.